The effect of rifampicin and pyrazinamide on isoniazid pharmacokinetics in rats

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 8, 2007, Pages 409-413

  Baldan, Helen M ^a   De Rosa, Helene J ^a   Brunetti, Iguatemy L ^a   Ximenes, Valdecir F ^a   Machado, Rosângela G P ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Isoniazid; Pharmacokinetics; Pyrazinamide; Rifampicin

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; MALE; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; HALF-LIFE; ISONIAZID; MALE; PYRAZINAMIDE; RATS; RATS, WISTAR; RIFAMPIN;

EID: 36448930197     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.570     Document Type: Article

References (20)

1. Brazil Ministério da Saúde. Manual de normas para o controle da tuberculose. J Pneumol 1997; 2: 281-310.
2. Taneja DP, Kaur D. Study on hepatotoxicity and other side-effects of antituberculosis drugs. J Indian Med Assoc 1990; 88: 278-280.
3. Douglas JG, Mcleod MJ. Pharmacokinetic factors in the modern drug treatment of tuberculosis. Clin Pharmacokinet 1999; 37: 127-146.
4. Davies DM, Ferner RE, Glanvile H. Textbook of Adverse Drug Reactions (5th edn). Chapman & Hall Medical: London, 1998; 290-292.
5. Castillo J, Lema M, Camaselle L, et al. Hepatotoxicidad por isoniacida. Rev Esp Enf Ap Digest 1981; 60: 595-602.
6. Peretti E, Karlaganis G, Lauterburg BH. Increased urinary excretion of toxic hydrazino metabolites of isoniazid by slow acetylators. Effects of a slow-release preparation of isoniazid. Eur J Clin Pharmacol 1987; 33: 283-286.
7. Timbrell JA, Mitchell JR, Snodgrass WR, Nelson SD. Isoniazid hepatotoxicity: the relationship between covalent binding and metabolism in vivo. Pharmacol Exp Ther 1980; 213: 364-369.
8. Boxenbaum HG, Riegelman S. Determination of isoniazid and metabolites in biological fluids. J Pharm Sci 1974; 63: 1191-1197.
9. Kashuba ADM, Bertino JS, Kearns GL, et al. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. Clin Pharmacol Ther 1998; 63: 540-551.
10. Huang Y, Chern H, Wu J, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37: 924-930.
11. Hardman JG, Limbird LE. Goodman & Gilman: as Bases Farmacológicas da Terapêutica (10th edn). McGraw Hill: Rio de Janeiro, 2004; 955-961.
12. Parthasarathy R, Sarma GR, Janardhanam B, et al. Hepatic toxicity in south Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1986; 67: 99-108.
13. Nishimura Y, Kurata N, Sakurai E, Yasuhara H. Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. J Pharmacol Sci 2004; 96: 293-300.
14. Sharma SK. Antituberculosis drugs and hepatotoxicity. Infect Genet Evol 2004; 4: 167-170.
15. Rey E, Gendrel D, Treluyer JM, et al. Isoniazid pharmacokinetics in children according to acetylator phenotype. Fundam Clin Pharmacol 2001; 15: 355-359.
16. Skakun NP, Shman'ko VV. Synergistic effect of rifampicin on hepatotoxicity of isoniazid. Antibiot Med Biotekhnol 1985; 30: 185-189.
17. Yue J, Peng R, Yang J, Kong R, Liu J. CYP2E1 mediated isoniazid-induced hepatotoxicity in rats. Acta Pharmacol Sin 2004; 25: 699-704.
18. Chow SC, Liu H. On sample size calculation in bioequivalence trials. J Pharmacokinet Pharmacodyn 2001; 28: 155-169.
19. Seifart HI, Gent WL, Parkin DP, Van Jaarsveld PP, Donald PR. High-performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids. J Chromatogr B 1995; 674: 269-275.
20. Jain A, Mehta VL, Kulshrestha S. Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis. Tubercle Lung Dis 1993; 74: 87-90.